Journal of Dermatological Treatment

Papers
(The H4-Index of Journal of Dermatological Treatment is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
The hf-PGA is a valid and reliable measure of hand/foot psoriasis severity in adults: results from a phase 2b clinical trial72
Topical delgocitinib for the treatment of chronic hand eczema68
Tildrakizumab 200 mg: a step forward in psoriasis treatment with added metabolic benefits62
Practical considerations relevant to treatment with the gene therapy beremagene geperpavec-svdt for dystrophic epidermolysis bullosa50
Lessons from a decentralized trial in atopic dermatitis: promises and perils45
Ruxolitinib cream monotherapy for facial and/or neck atopic dermatitis: results from a decentralized, randomized phase 2 clinical trial39
Skin type classifications: does the perfect assessment exist?36
A systematic review of recent randomized controlled trials for palmoplantar pustulosis34
Pretreatment Demodex infestation predicts dupilumab-associated blepharoconjunctivitis in atopic dermatitis31
Response to fumaric acid esters for plaque type psoriasis in real-world practice is largely independent of patient characteristics at baseline – a multivariable regression analysis from the German Pso30
Long-term real-world evidence of SB5 (adalimumab biosimilar) treatment in patients with moderate-to-severe psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Regist27
Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab25
Artificial intelligence-based prescription of personalized scalp cosmetics improved the scalp condition: efficacy results from 100 participants25
Ixekizumab-induced interstitial lung disease: a case report confirmed by transbronchial lung cryobiopsy24
Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24–28 and 48–52 weeks24
Patients’ preferences for systemic treatment of atopic dermatitis: safety and efficacy count the most23
Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study)23
The effect of tildrakizumab on adipokines production in patients affected by psoriasis and obesity: preliminary results from a single center real-life study22
The efficacy and safety of low-dose rituximab in the treatment of pemphigus vulgaris: a cohort study21
Driving taxis21
Clinical observation of 10 cases of stable non-segmental vitiligo in adults treated with upadacitinib21
0.22891712188721